PDCD1 and melanoma: This phenomenon has been observed in pre-clinical models of non-small cell lung cancer, melanoma, and pancreatic cancer, as well as an autologous humanized mouse model of renal cell carcinoma in response to anti-PD-1 antibody therapy but not anti-CTLA-4 antibody therapy or chemotherapy.